To further elucidate the mechanism of action of LF in treating NAFLD and DM comorbidity, the top five pathways, mTOR, MAPK, FoxO, PI3K‐Akt, and Phospholipase D signaling pathways, were selected based on the number of enriched genes and displayed in a network diagram (Figure 2D). The gene discussed is AKT1; the disease is metabolic dysfunction-associated steatotic liver disease.